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Background: Cerium oxide (CeO2) nanoparticles have been posited to have both beneficial
and toxic effects on biological systems. Herein, we examine if a single intratracheal instillation
of CeO2 nanoparticles is associated with systemic toxicity in male Sprague-Dawley rats.
Methods and results: Compared with control animals, CeO2 nanoparticle exposure was
associated with increased liver ceria levels, elevations in serum alanine transaminase levels,
reduced albumin levels, a diminished sodium-potassium ratio, and decreased serum triglyceride
levels (P , 0.05). Consistent with these data, rats exposed to CeO2 nanoparticles also exhibited
reductions in liver weight (P , 0.05) and dose-dependent hydropic degeneration, hepatocyte
enlargement, sinusoidal dilatation, and accumulation of granular material. No histopathological alterations were observed in the kidney, spleen, and heart. Analysis of serum biomarkers
suggested an elevation of acute phase reactants and markers of hepatocyte injury in the rats
exposed to CeO2 nanoparticles.
Conclusion: Taken together, these data suggest that intratracheal instillation of CeO2
nanoparticles can result in liver damage.
Keywords: cerium oxide nanoparticles, systemic toxicity, hepatic toxicity, hydropic
degeneration

Introduction
Cerium is a rare earth lanthanide metal and a strong oxidizing agent. Cerium exists
both in the trivalent state (Ce3+, cerous) and very stable tetravalent state (Ce4+, ceric)
as cerium oxide (CeO2).1 CeO2 is widely used as a polishing agent for glass mirrors,
television tubes, and ophthalmic lenses.2 In addition, CeO2 can also act as a catalyst
because it can both accept and donate oxygen.3 This latter property has led to the widespread use of CeO2 in the automobile industry, where it has been used to increase fuel
efficiency and reduce particulate emissions.4–6 It appears that CeO2 nanoparticles may
also be capable of acting as antioxidants, which has led some to postulate that these
particles may be useful for the treatment of cardiovascular disease,7 neurodegenerative
disease,8 and radiation-induced tissue damage.9,10 Nonetheless, other in vitro work has
shown that CeO2 nanoparticles can also cause oxidative stress.11
The Organization for Economic Co-operation and Development Working Party
on Manufactured Nanomaterials has demarcated CeO 2 nanoparticles along with
14 other nanoparticles as a high-priority for evaluation.12 Given current industrial
applications, it is thought that the most common route of CeO2 exposure is likely to
be through inhalation and/or ingestion. Although previous studies have shown that
intratracheal instillation of CeO2 nanoparticles can cause a toxicological response
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in the lung, whether these particles also exhibit systemic
toxicity is currently unclear.2,13 Therefore, the purpose of the
current study was to determine if the intratracheal instillation
of CeO2 nanoparticles is associated with alterations in the
indices of systemic toxicity and pathological change. On the
basis of previous work examining the translocation of carbon
nanotubes from the lung,14 we hypothesized that intratracheal
instillation of CeO2 nanoparticles could lead to nanoparticle
deposition in other organs through the circulation. Consistent
with this hypothesis, our data suggest that the intratracheal
instillation of CeO2 nanoparticles is associated with increased
liver ceria levels, reductions in liver weight, and evidence of
liver damage.

Materials and methods
Particle characterization
CeO2 nanoparticles, 10 wt% in water (average diameter
approximately 20 nm), were obtained from Sigma-Aldrich
(St Louis, MO) as previously outlined.13 Normal saline
was used as vehicle to suspend the nanoparticles prior to
instillation. CeO2 samples diluted in saline were used for animal exposures. Since the CeO2 nanoparticles form agglomerates in suspension, the size distribution of the agglomerates
of CeO2 was analyzed using field emission scanning electron
microscopy and transmission electron microscopy (TEM).
The CeO2 suspension was analyzed using field emission
scanning electron microscopy as follows: the CeO2 particle
suspensions were diluted with distilled water (about 10-fold)
and were dried on carbon planchet and sputter-coated. After
sputter-coating, the specimens were examined with a Hitachi
Model S-4800 field emission scanning electron microscope
(Schaumburg, IL) between 5 kV and 20 kV. In addition, the
particles were diluted in double distilled filtered water and a
drop was placed on a formvar-coated copper grid to dry before
viewing the samples with a JEOL 1220 TEM (Tokyo, Japan).

Animal handling and instillation
of CeO2 nanoparticles

Specific pathogen-free male Sprague-Dawley (Hla: SD-CVF)
rats (6 weeks old) were purchased from Hilltop Laboratories
(Scottdale, PA). Rats were kept in cages individually and
ventilated with HEPA filtered air in an animal facility accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. After acclimatization
for one week, the rats were randomly divided into four groups
(n = 7 per group) to receive vehicle control (saline, 0.9% NaCl),
or instillation of 1.0, 3.5, or 7.0 mg/kg CeO2 nanoparticles.
Rats were anesthetized with sodium methohexital (35 mg/kg,
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intraperitoneally) and placed on an inclined restraint board
before instillation with 0.3 mL of saline suspension or CeO2
nanoparticles. The animals were euthanized 28 days postexposure by drug overdose according to the Guide for the
Care and Use of Laboratory Animals and as approved by the
National Institute for Occupational Safety and Health Animal
Care and Use Committee. All animals were humanely treated
and were monitored for any potential suffering.

Determination of cerium content
in the liver
Liver cerium content was estimated by induction coupled
plasma-mass spectrometry (ICP-MS) at Elemental Analysis
Inc (Lexington, KY) according to the standard protocol.14
Briefly, liver samples (n = 4 for each group) were prepared
using Environmental Protection Agency method 3050B for
the analysis of total cerium by ICP-MS. A 2.5 g sample was
weighed to the nearest 0.0001 g and digested with concentrated nitric acid, 30% hydrogen peroxide, and concentrated
hydrochloric acid. A method blank, laboratory control
sample, a laboratory duplicate, and a predigestion matrix
spike were prepared for each sample. After digestion, the
extracts and the quality control samples were diluted to a
final volume of 50 mL before analysis using an Agilent
7500cx ICP-MS. The instrument was calibrated for Ce-140
with 0, 0.1, 1.0, 10.0, and 100 µg/L standards prepared from
a certified reference standard traceable to National Institute
of Standards and Technology reference materials. A second
source calibration verification standard traceable to National
Institute of Standards and Technology reference materials
was analyzed to verify the calibration standards. A continuing
calibration verification standard and a continuing calibration
blank were analyzed at the beginning of the run, after every
ten samples, and at the conclusion of the run.

Serum biochemical and lipid
profile analysis
Blood was collected by cardiac puncture into a serum collection tube (BD Vacutainer®) before centrifugation at 800× g
for 15 minutes. Serum was collected and used for biochemical
assays using an Abaxis VetScan® analyzer (Abaxis, Union
City, CA). Serum biochemical parameters, ie, alanine aminotransferase, alkaline phosphatase, bilirubin, blood urea
nitrogen, albumin, calcium (Ca2+), creatinine, amylase,
globulin, potassium (K+), sodium (Na+), phosphorus, total
bilirubin, and total protein were evaluated with a Comprehensive Diagnostic Profile Disk. The lipid profile, ie, total
cholesterol, triglycerides, and high-density lipoprotein was
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measured using lipid profile-Glu cassettes (Cholestech LDX)
and a Cholestech LDX® analyzer. The remaining serum was
stored at -80°C.

Multiplexed serum protein immunoassays
Pooled serum samples from all seven animals in each
experimental group were shipped on dry ice to Rules-Based
Medicine (Austin, TX) for Rodent MAP® version 2.0 antigen analysis using a Luminex 100 instrument, as detailed
elsewhere.14 The antigen panel consisted of 59 proteins,
which included proteins involved in inflammation, cytokines,
growth factors, and tissue factors. Each analyte was quantified using 4 and 5 parameter, weighted and nonweighted
curve fitting algorithms using proprietary data analysis
software developed at Rules-Based Medicine.

Tissue collection and histopathological
examination
Liver, kidney, spleen, and heart were collected at the
time of death. Each tissue was weighed and then fixed in
FineFIX™ (Milestone medicals, Shelton, CT) preservative for later histopathological examination. Tissues from
liver, spleen, kidney, and heart were embedded in paraffin
wax, sectioned at 5 µm, mounted on glass slide and stained
with hematoxylin-eosin using standard histopathological
techniques. Sections were examined by light microscopy in
a blinded fashion by a board certified pathologist.

Data analysis

Results are presented as the mean ± standard error of the
mean. Data were analyzed using the SigmaPlot 11.0 statistical program. One-way analysis of variance was performed
for overall comparisons, while the Student–Newman–Keuls
post hoc test was used to determine differences between
groups. Values of P , 0.05 were considered to be statistically significant.

Results
Nanoparticle characterization
Similar to previous work using the same batch of CeO2
nanoparticles,13 analysis of nanoparticle size by TEM and
scanning electron microscopy confirmed the presence of
single and agglomerated CeO2 nanoparticles in the suspensions (Figure 1A and B). Field emission scanning electron
microscopy showed that the CeO 2 nano particles were
generally dispersed into submicron groups with an average
size of 9.26 ± 0.58 nm. The diameter of the primary CeO2
particles was determined to be 10.14 ± 0.76 nm by TEM.

International Journal of Nanomedicine 2011:6

Figure 1 Characterization of the cerium oxide nanoparticles by (A) field
emission scanning electron microscopy and (B) transmission electron microscopy
(scale bar = 200 nm) of a dilute cerium oxide suspension.

CeO2 instillation decreases
liver wet weight
CeO2 instillation at the 1, 3.5, or 7 mg/kg dosages had no
significant effect on rat body, heart, kidney, or spleen weight
(Table 1). Compared with control animals, only the highest CeO2 dosage (7 mg/kg) decreased liver weight (saline
control 14.55 ± 0.27 versus CeO2 7.0 mg/kg 12.50 ± 0.54;
P , 0.05, Table 1).

CeO2 instillation increases
liver ceria content
The ceria content of animals instilled with 7.0 mg/kg CeO2
nanoparticles was higher than that observed in the other
groups (saline control nondetectable versus 1.0 mg/kg CeO2:
0.05 ± 0.01 ppm versus 3.5 mg/kg CeO2: 0.11 ± 0.02 ppm versus
CeO2 7.0 mg/kg: 0.50 ± 0.18 ppm; P , 0.05; Figure 2).

Effect of CeO2 instillation
on serum biochemical profile
Table 2 shows the alterations of the serum biochemical parameters following CeO2 nanoparticle exposure. Compared with
control animals, CeO2 instillation at 1, 3.5, or 7 mg/kg diminished the sodium to potassium ratio (P , 0.05), while the CeO2
dosage of 7 mg/kg increased serum alanine aminotransferase
levels and reduced albumin levels (P , 0.05). The serum lipid
profile analysis (Table 2B) indicated a reduction in the triglyceride levels with 7 mg/kg CeO2 nanoparticle exposure.

CeO2 nanoparticle exposure is associated
with evidence of liver pathology
The primary alterations considered for liver tissue damage
were hydropic degeneration of the hepatocytes, dilation
of the sinusoids, portal inflammation, and fibrosis of the
liver compared to tissues obtained from control animals.
CeO2 nanoparticle exposure showed widespread hydropic
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Table 1 Alterations in absolute organ wet weight 28 days after intratracheal instillation of cerium oxide nanoparticles
Organ weight (g)

Saline control
(n = 7)

CeO2 1.0 mg/kg
(n = 7)

CeO2 3.5 mg/kg
(n = 7)

CeO2 7.0 mg/kg
(n = 7)

Heart (g)
Liver (g)
Kidney (g)
Spleen (g)

1.52 ± 0.15
14.55 ± 0.27
2.67 ± 0.31
0.58 ± 0.06

1.35 ± 0.05
14.30 ± 1.04
2.55 ± 0.21
0.65 ± 0.10

1.27 ± 0.07
14.78 ± 0.57
2.54 ± 0.33
0.56 ± 0.08

1.23 ± 0.05
12.50 ± 0.54*
2.43 ± 0.31
0.64 ± 0.04

Note: *Significantly different from vehicle control (P , 0.05).

degeneration of hepatocytes around the central vein region
with sparing of the immediate periportal region (Figure 3).
These changes were panlobular in nature. Along with
hydropic degeneration, we also observed enlargement of the
hepatocytes, enlargement of the nucleus in the hepatocyte,
binucleation of some hepatocytes, dilatation of the sinusoids,
and occasional focal inflammation areas in a few of the
exposed animals (Figure 4). As the dose of the nanoparticles
was increased, the number of hepatocytes that show hydropic
degeneration was also elevated suggesting that changes in
hepatocyte structure were dose-dependent.

CeO2 nanoparticle exposure does not
appear to affect spleen, kidney, and heart
Alterations considered for the kidney pathologies were
necrosis of the proximal tubular epithelium, tubular accumulation of proteinaceous material, and inflammatory reaction
in the interstitial areas of the cortex and medulla. Spleen
and heart tissues were examined for any histological alterations in structure along with the infiltration of inflammatory
cells. We did not observe any alterations in the histological
appearance or the infiltration of inflammatory cells in the
kidney, spleen, and heart with CeO2 nanoparticle exposure
(Figures 5–7).

Cerium concentration (ppm)

0.80

*

0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
Control

CeO2
1.0 mg/kg

CeO2
3.5 mg/kg

CeO2
7.0 mg/kg

Figure 2 Concentration of cerium in liver after intratracheal instillation of cerium
oxide nanoparticles.
Note: *Significantly different from the vehicle control (P , 0.05).
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Effect of CeO2 instillation
on serum protein expression
A panel of 59 protein biomarkers comprising cytokines,
inflammatory markers, growth factors, and tissue factors
were quantified in the serum samples collected in this study
using the RBM RodentMAP® V2.0 multiplex immune assay
service. Compared with levels observed in the control animals, the levels of 16 different analytes appeared to exhibit
a trend towards being increased or decreased by at least 15%
or more following the instillation procedure with the CeO2
nanoparticles (Figure 8A, B, and C). At the 7.0 mg/kg CeO2
dosage, ten of the analytes (fibroblast growth factor-basic,
haptoglobin, immunoglobulin A, interleukin-11, matrix metalloproteinase-9, myoglobin, serum amyloid protein, serum
glutamic oxaloacetic, transaminase thrombopoietin, and
von Willebrand factor) exhibited a trend towards increased
expression whereas two (tumor necrosis factor-related activation protein (CD-40 L) and interleukin-7) appeared to exhibit
a trend towards decreased expression (Figure 8C).

Discussion
Investigation of the effects that nanomaterials may have on
cellular function is essential for ensuring that the utilization
of these materials in industrial or medical applications is safe.
Although CeO2 nanoparticles have demonstrated excellent
potential for biomedical use,7,8,10 limited knowledge exists
concerning their potential systemic toxicity. The primary
finding of this investigation was that intratracheal instillation
of CeO2 nanoparticles (Figure 1) results in increased liver
ceria levels (Figure 2), and that these changes in liver ceria are
associated with evidence of liver pathology (Figures 3 and 4),
decreases in liver weight (Table 1), and alterations in blood
chemistry (Table 2). Consistent with other reports examining
CeO2,15 titanium dioxide,16 silica,17 and copper18 nanoparticles, our data suggest it is possible that CeO2 nanoparticles
are capable of translocating from the lung to the liver via the
circulation.
The histopathological appearance of the liver following CeO2 nanoparticle instillation is consistent with
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Table 2 Changes in serum biochemical parameters (A) and lipid profile (B) 28 days after the intratracheal instillation of cerium oxide
nanoparticles
Analyte
A
Glucose
ALP
ALT
Amylase
Total protein
Albumin
Globulin
ALB-GLOB ratio
BUN
Creatinine
Ca2+
Phosphorus
Na+
K+
Na+-K+ ratio

Saline control
(n = 7)

CeO2 1.0 mg/kg
(n = 7)

CeO2 3.5 mg/kg
(n = 7)

CeO2 7.0 mg/kg
(n = 7)

186.4 ± 25.7
276.1 ± 53.7
58.3 ± 10.7
974.7 ± 97.4
6.0 ± 0.1
4.2 ± 0.2
1.8 ± 0.2
2.3 ± 0.3
15.4 ± 1.1
0.3 ± 0.1
11.4 ± 0.7
8.6 ± 0.9
142.3 ± 0.9
5.5 ± 0.4
25.8 ± 2.0

208 ± 43.0
263 ± 55.4
83.4 ± 28.5
1055.1 ± 124.2
5.9 ± 0.6
4.1 ± 0.5
1.8 ± 0.2
2.3 ± 0.3
15 ± 3.1
0.27 ± 0.1
10.7 ± 1.3
7.9 ± 1.2
138 ± 10.7
6.0 ± 0.5
22.9 ± 1.7*

197.6 ± 40.2
242 ± 35.3
88.3 ± 31.4
991.4 ± 116
6.2 ± 0.5
4.5 ± 0.4
2.0 ± 0.2
2.2 ± 0.3
15.7 ± 1.9
0.23 ± 0.1
11.5 ± 1.1
8.7 ± 1.0
138.1 ± 10.7
6.5 ± 0.6
21.2 ± 1.4*

231 ± 93.5
222.23 ± 81.9
130.5 ± 94.5*
908.4 ± 277.0
5.4 ± 1.3
3.5 ± 1.1*
1.8 ± 0.2
1.9 ± 0.6
14.4 ± 4.2
0.28 ± 0.1
10.4 ± 2.4
8.2 ± 1.9
132.1 ± 16.3
5.8 ± 0.9
22.8 ± 2.5*

100.7 ± 1.9
143 ± 53
21 ± 6.0

100 ± 0
109.6 ± 50.9
19.4 ± 5.4

100 ± 0
190.3 ± 83.7
20 ± 6.4

103.1 ± 8.3
93.1 ± 22.3*
19 ± 5.1

B
Total cholesterol
Triglycerides
HDL

Note: *Significantly different from the vehicle control (P , 0.05).
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ALB-GLOB ratio, albumin to globulin ratio; BUN, blood urea nitrogen; Ca, calcium; Na, sodium;
K, potassium; Na-K ratio, sodium to potassium ratio; HDL, high density lipoproteins.

the p ossibility that ceria can induce several different
pathological alterations, including hydropic degeneration
of hepatocytes, enlargement of hepatocytes, dilatation of
the sinusoids, and nuclear enlargement (Figures 3 and 4).
There was no evidence of granuloma, portal inflammation,

A

B

C

D

100 µm

Figure 3 Cerium oxide nanoparticle exposure alters histopathological architecture
of the liver. (A) Saline control (400×), (B) CeO2 at 1.0 mg/kg (400×), (C) CeO2
3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×). Note evidence of hydropic
degeneration (arrow) with CeO2 instillation.

International Journal of Nanomedicine 2011:6

fibrosis, or bile duct abnormalities, except for the presence
of some local inflammation of the lobules in some
animals.
Because the liver is the major organ for biotransformation of toxins, it may be the first organ to be exposed to
nanoparticles that are able to enter into the circulation. It
is thought that hydropic degeneration can be caused by
hypoxia,19 ischemia,20 or the treatment of hepatocytes with
endotoxins21 or chemicals.22 Consistent with our findings,
this response has also been observed following exposure
to other toxic materials, including copper nanoparticles23
and carbon tetrachloride,24 or following the inhalation of
anesthetics such as sevofulrane and desflurane.25 How
exposure to CeO 2 nanoparticles may induce hydropic
degeneration or if these changes are reversible is currently
unclear. Sinusoidal dilatation is the increased gap between
the hepatic cords in the hepatic lobule that has also been
observed in aluminum-induced hepatic toxicity,26 carbon
tetrachloride-induced hepatic toxicity,27 and ischemia,28
as well as with the organophosphate insecticide, methidathion.29 In addition, we also noted the accumulation of
granular material inside the hepatocytes which appeared
to be dose-dependent and perhaps related to reduction of
liver weight (Table 1).
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A

B

C

100 µm
Focal inflammation

Arrow: sinusoidal dilatation

Arrow: binucleation

Figure 4 Histopathological alterations with the CeO2 nanoparticle exposure (7.0 mg/kg) include (A) focal inflammation, (B) sinusoidal dilatation, and (C) binucleation of
the hepatocyte (400×).

A

B

C

D

100 µm

Figure 5 Cerium oxide nanoparticle exposure has no effect on the histological
appearance of the kidney. (A) Saline control (400×), (B) CeO2 at 1.0 mg/kg (400×),
(C) CeO2 3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×).

A

B

C

D

100 µm

Figure 6 Cerium oxide nanoparticle exposure has no effect on the histological
appearance of the spleen. (A) Saline control (400×), (B) CeO2 at 1.0 mg/kg (400×),
(C) CeO2 3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×).
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Our serum biochemical profile data suggest that CeO2
nanoparticle instillation in the rat may be associated with an
elevation of alanine aminotransferase and reduction in albumin (Table 2). It is well established that hepatocyte damage
is associated with the release of liver enzymes into the circulation and reduced albumin levels.26 In addition to changes
in the level of circulating liver enzymes, CeO2 nanoparticle
instillation also appears to decrease the sodium-potassium
ratio and the amount of triglycerides (Table 2).
Similar to other work examining other types of nano
particles,30,31 we observed a trend towards an increasing
serum concentration of haptoglobin (16%), serum amyloid
P protein (24%), and von Willebrand factor (33%) following
exposure to CeO2 nanoparticles. Consistent with our histopathological findings, and the possibility of hepatic injury,
we also found evidence that CeO2 nanoparticle instillation

A

B

C

D

100 µm

Figure 7 Cerium oxide nanoparticle exposure has no effect on histological
appearance of heart. (A) saline control (400×), (B) CeO2 at 1.0 mg/kg (400×),
(C) CeO2 3.5 mg/kg (400×), and (D) CeO2 7.0 mg/kg (400×).
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Figure 8 Cerium oxide nanoparticles exposure results in alterations in the expression of serum protein biomarkers.

was associated with a trend toward increases in the amount
of serum thrombopoietin, fibroblast growth factor, serum
glutamic oxaloacetic transaminase, and transaminase thrombopoietin (Figure 4). Elevation in these serum biomarkers is
thought to be highly correlated with acute hepatic injury.22,32
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Taken together, these data suggest that ceria deposition may
be associated with liver damage. Given our findings that
CeO2 nanoparticle instillation, at least at the levels used
in the current study, does not induce appreciable damage
to the heart, kidney, or spleen. It is possible that the liver,
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by acting to clear CeO2 nanoparticles from the circulation,
is functioning to prevent additional secondary or tertiary
pathological changes elsewhere.

Conclusion
In summary, our data suggest that intratracheal instillation of
CeO2 nanoparticles may be associated with hepatotoxicity.
The toxicity induced by CeO2 nanoparticles appears to be
dose-dependent, because the rats instilled with 7.0 mg/kg
body weight of CeO2 nanoparticles exhibited the greatest
evidence of toxicological response. The t oxicological
response appears to be limited to the liver and may
occur through extrapulmonary translocation of the CeO2
nanoparticles into the systemic circulation. Given these
findings, additional research to evaluate the health effects
of CeO2 nanoparticles is likely warranted.
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